Coherus Oncology (CHRS) Short term Debt (2014 - 2023)

Coherus Oncology (CHRS) reported Short term Debt of $3.3 million for Q4 2023, down 18.32% sequentially from $4.0 million in Q3 2023.

Coherus Oncology (CHRS) Short term Debt (2014 - 2023) Analysis & Trends

Coherus Oncology (CHRS) has 6 years of Short term Debt data on file, last reported at $3.3 million in Q4 2023.

For the quarter ending Q4 2023, Short term Debt changed N/A year-over-year to $3.3 million; the trailing twelve-month figure through Dec 2023 stood at $3.3 million (changed N/A YoY), and the FY2023 full-year result was $3.3 million, changed N/A from the prior year.
Short term Debt declined to $3.3 million in Q4 2023, from $4.0 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $17.3 million in Q3 2021 to a low of $3.3 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Coherus Oncology	195.05 Mn	28.00 Mn	8.50 Mn

Download Data